What Алпростан treats: Main Uses and Benefits

Алпростан (Alprostadil) is commonly used to provide specialized, targeted support by enhancing localized blood circulation. This focused action supports its use across distinct, specialized clinical domains that share the common need for robust vascular intervention. The primary uses are recognized across major medical domains, including specialized applications in the treatment of erectile dysfunction and critical care for newborns.

---

Support for Refractory and Severe Erectile Dysfunction

This medication is applied in situations involving the consistent failure to achieve or maintain a functional penile erection, particularly in situations where the symptoms are related to localized functional stress. The primary benefit is the provision of support to enhance localized blood flow, which may assist men in managing the symptoms that interfere with daily functioning. This application is commonly used when oral therapies are ineffective or inappropriate, providing an essential supportive solution for symptoms that create noticeable functional strain.

Critical Stabilization of Newborn Circulatory Instability

In newborns, the drug serves a specialized role by addressing critical congenital heart defects that require an open ductus arteriosus for adequate blood flow. This specialized use provides the essential therapeutic benefit of assisting with the functional stability of systemic and pulmonary circulation, supports the patient during the critical phase before surgical correction, and contributes to improved day-to-day comfort during symptomatic periods. This is an acute application in conditions associated with acute or disruptive episodes.

Adjuvant Relief for Advanced Peripheral Tissue Ischemia

Алпростан is relevant as part of conventional therapy for chronic and severe peripheral arterial occlusive diseases, which are conditions presenting with systemic or localized discomfort in the limbs. The treatment is commonly used to help with severe manifestations like non-healing ulcers and rest pain, offering support to improve microcirculation and contribute to easing the overall symptom load in the extremities. This may assist with symptoms related to localized functional stress.

---

Summary of Therapeutic Applications:

The primary therapeutic applications of Alprostadil are centered on managing complex symptomatic patterns in severe erectile dysfunction, critical circulatory restriction in newborns, and advanced peripheral limb ischemia.

“This medication is applied in clinical settings that involve acute or unstable symptom patterns, which require targeted symptomatic support to help maintain functional stability.”

Quick Fact: Relief for Vascular Dysfunction

The specialized vasodilating effect of Alprostadil is commonly applied when symptoms are related to localized functional stress where additional symptomatic support is needed.

The eligibility for Alprostadil (Алпростан) is strictly defined by regulatory documents, targeting specific medical needs and populations. Use is primarily established for Adult Males in the treatment of erectile dysfunction and for Neonates requiring temporary maintenance of a patent Ductus Arteriosus for survival.

---

Contraindicated Populations

Absolute contraindications prohibit use in several patient groups. These include men with a known hypersensitivity to the drug, those with penile implants, and men who have conditions that predispose them to priapism, such as Sickle Cell Anemia, Multiple Myeloma, or Leukemia. Use is also contraindicated in men with fibrotic conditions of the penis, including Peyronie’s disease and cavernosal fibrosis. For the neonatal indication, the drug is contraindicated if the diagnosis is Respiratory Distress Syndrome.

---

Restricted and Non-Eligible Groups

The medicine is not indicated for use in women, children, or adolescents outside of the critical neonatal application. Conditional restrictions apply to other groups, including patients with hepatic or renal impairment, where caution is advised and dose adjustments may be necessary. Use is also restricted for patients taking anticoagulants due to the increased risk of injection site bleeding.

Interactions with other medicines and products

The official regulatory profile for Алпростан (Alprostadil) outlines specific interaction constraints primarily related to its potent vasodilatory and antiplatelet effects.

Interacting Product Categories

The co-administration of Алпростан with antihypertensive agents (including vasodilators) may result in an enhanced or potentiated hypotensive effect. Caution is required when using these combinations due to the risk of additive blood pressure lowering.

Concurrent use with anticoagulants (such as warfarin or heparin) and antiplatelet agents carries a documented risk of increased bleeding or injection site hematoma, resulting from Алпростан's inhibitory effect on platelet aggregation. This combination requires careful management.

Combination Therapy Restrictions

The safety and efficacy of combining Алпростан with other vasoactive agents administered through intracavernosal injection have not been systematically studied, and the use of such combinations is not recommended in official labeling. This specifically includes other medicines intended for the treatment of erectile dysfunction.

Pharmacokinetic Basis: Regulatory documents note that the potential for pharmacokinetic drug-drug interactions between Alprostadil and other orally or intracavernosally administered agents has not been formally studied.

Targeted Receptor Agonism and Intracellular Signaling

The mechanism of Алпростан begins with its active ingredient, Alprostadil, functioning as a direct agonist on specific Prostaglandin E receptors ( EP2 and EP4) found on the surface of vascular smooth muscle cells. This interaction rapidly activates the enzyme Adenylate Cyclase, resulting in increased production of the key second messenger cyclic AMP ( cAMP) within the cell.

---

cAMP Cascade and Vascular Smooth Muscle Relaxation

The high concentration of cAMP is integral to the mechanistic pathway, as it initiates a cascade that leads to a decrease in the level of free calcium ions ( Ca^2+) inside the muscle tissue. The reduction in Ca^2+ concentration causes the vascular and trabecular smooth muscle to relax .

---

Localized Perfusion Enhancement and Hemodynamic Control

The resulting relaxation of the arterial smooth muscle leads to a significant increase in localized blood flow, effectively increasing local perfusion—the supply of blood to the target tissue. This hemodynamic effect is necessary, but it is intrinsically limited by the body’s rapid inactivation mechanisms, specifically pulmonary first-pass metabolism, which necessitates highly localized administration to ensure sufficient therapeutic concentration.

How to Use Алпростан (Alprostadil): Official Administration Guidelines

Alprostadil administration is highly specialized, depending strictly on the clinical application, and must follow precise procedures. Initial dosing for all indications requires strict medical supervision.

Official Routes of Administration

The medicine is administered using distinct methods tailored to the target area:

• Intracavernosal Injection: Administered directly into the penis for erectile dysfunction (ED).
• Intraurethral Insertion: Applied via a suppository inserted into the urethra for ED.
• Continuous Intravenous (IV) Infusion: Reserved for critical care in neonates to maintain circulation.

Standard Dosing and Frequency

Dosing is determined by a physician through a titration process, aiming to identify the lowest effective dose (LED) that achieves the desired response without excess duration.

Application	Starting Dose (Typical)	Maximum Frequency	Preparation Requirement
ED (Intracavernosal)	1.25 to 2.5 mcg	No more than 3 times per week	Requires reconstitution with sterile diluent.
ED (Intraurethral)	125 to 250 mcg	No more than 2 times in 24 hours	Inserted into the urethra.
Neonatal IV Infusion	0.05 to 0.1 mcg/ kg/ min	Continuous (at reduced maintenance rate)	Requires dilution before infusion.

Procedural and Setting Requirements

All doses for ED are used on an as-needed basis. The intracavernosal injection must be administered into the dorso-lateral aspect of the proximal third of the penis, with the injection site alternated for each use. The initial determination of the correct dosage for ED must be conducted in a physician’s office. For neonates, the IV infusion must be administered in a facility providing intensive pediatric care at all times.

Research evidence / Overview of studies for Алпростан

Evidence for Stabilization of Newborn Circulatory Instability

Alprostadil was studied for use in newborns (neonates) who have critical congenital heart defects. These conditions are characterized by systemic or functional imbalance that requires specialized acute management. The research examining this specialized application primarily consists of descriptive case series and observational studies, including trials that explored dose-response patterns in this population.

Researchers primarily monitored acute changes related to physiological strain or stress. The main outcomes measured involved confirming the maintenance of ductal patency (an anatomical opening) and monitoring the patient's vital status until a surgical correction could be performed. What remains uncertain is the existence of placebo-controlled research, as ethical constraints preclude the evaluation against a placebo in this acute setting.

---

Evidence for Advanced Peripheral Tissue Ischemia

Alprostadil was evaluated in patients with Advanced Peripheral Arterial Occlusive Disease (PAOD), a condition marked by functional limitations and outcomes related to physical discomfort in the limbs. The research base includes Randomized Controlled Trials (RCTs) and Systematic Reviews that have explored outcomes related to ulcer healing, amputation rates, and the measurement of rest pain.

Studies explored the treatment in populations where symptoms may vary in intensity. The primary outcomes the research examined included the rate of major amputations and the proportion of patients whose ischemic ulcers healed. Results from certain large, contemporary RCTs reported that findings were mixed, suggesting that data may show patterns related to some outcomes but no significant differences for the primary endpoints of major amputation and complete ulcer healing.

---

Evidence for Refractory Erectile Dysfunction

Alprostadil was studied for use in adult male patients with severe erectile dysfunction, a condition characterized by functional limitations. The evidence base relies on Randomized Controlled Trials (RCTs) and supporting Systematic Reviews.

Researchers examined outcomes related to physical discomfort and daily functioning. The primary outcomes measured included changes in erectile function scores using validated scales and the tracking of successful attempts at vaginal penetration. Evidence quality varies across studies, particularly when comparing different administration forms.

---

What Remains Undefined or Inconsistent in the Evidence

Research has explored the longevity of the effects. The available data are still emerging and research provides context but not individual predictions about the sustained effects. Long-term effects are not fully established because follow-up durations were limited in the most rigorous trials. Furthermore, the research findings apply only to the specific populations studied.

Common questions about Алпростан (FAQ)

Q: What should I do if my erection lasts longer than 4 hours after taking Alprostadil?

If an erection lasts between 4 and 6 hours, it is considered a prolonged erection, and an erection that persists for longer than 6 hours is classified as priapism. Official prescribing information recommends that patients immediately seek medical assistance for any erection persisting longer than 4 hours. This measure is intended to minimize the potential risk of permanent tissue damage associated with a prolonged erection.

Q: Does Alprostadil protect against sexually transmitted diseases?

No, regulatory information explicitly states that Alprostadil offers no protection against the transmission of sexually transmitted diseases (STDs), such as HIV, syphilis, or herpes. The labeling notes that if protection against STDs is desired, barrier methods should be used.

Q: What is the full trade name/brand name of Alprostadil?

Alprostadil is the active ingredient in several different products. Depending on the specific formulation and region, the medicine is marketed under various brand names, including Caverject, Caverject Impulse, Edex, and Muse.

Q: How long does the effect of Alprostadil last after injection?

According to official product information, the duration of the erection is related to the specific dose administered. The goal stated in the official product information is that the lowest effective dose should achieve an erection duration suitable for intercourse that does not exceed 1 hour.

Q: What are the very common side effects of the injection?

The most frequently reported adverse reaction (classified as 'very common') that is specific to the intracavernosal injection is pain in the penis. This pain is usually described as being mild to moderate in intensity and often occurs shortly after administration.

Q: Where exactly on the penis should the injection be placed?

The administration procedure outlined in official instructions specifies placement into the dorso-lateral aspect (the upper-side portion) of the proximal third of the penis (the part closest to the body). It is also noted that the injection site should be alternated for each use.

The storage and disposal of Alprostadil (Алпростан) are governed by specific regulatory requirements for product stability and safety.

Detail	Official Regulatory Requirement
Storage Temperature	Varies by form: 20 mcg powder must be stored at 20 C to 25 C. The 40 mcg powder is refrigerated until dispensed, then stored at or below 25 C.
Stability After Preparation	The reconstituted solution must be used within 24 hours when stored at or below 25 C.
Handling Restrictions	The medicine must not be frozen. The reconstituted solution must not be refrigerated. The solution must be visually inspected for precipitates and discoloration before use.
Disposal Instructions	Used needles and syringes must be immediately placed in an FDA-cleared sharps disposal container. Loose sharps must not be disposed of in household trash or down the drain.
Child Safety	The product and all associated supplies must be kept out of the reach of children.